<DOC>
	<DOCNO>NCT02044120</DOCNO>
	<brief_summary>The purpose study define dose-limiting toxicity maximum tolerate dose poly ADP-ribose polymerase inhibitor niraparib escalate dos temozolomide patient pre-treated incurable Ewing sarcoma .</brief_summary>
	<brief_title>ESP1/SARC025 Global Collaboration : A Phase I Study Combination PARP Inhibitor , Niraparib Temozolomide Irinotecan Patients With Previously Treated , Incurable Ewing Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Niraparib</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Poly ( ADP-ribose ) Polymerase Inhibitors</mesh_term>
	<criteria>Histologically confirm Ewing sarcoma Evidence Ewing sarcoma translocation FISH RTPCR . Must willing undergo tumor biopsy study entry biologic correlate . If patient &gt; 18 year , must willing undergo ontreatment tumor biopsy unless medically contraindicate Recurrent refractory tumor know curative treatment option accord judgment investigator . Age ≥ 13 year . Life expectancy ≥ 3 month . ECOG performance status 02 . Measurable disease CT MRI RECIST 1.1 . Adequate organ function Patients must receive minimum first line chemotherapy regimen consist least 2 follow agent : doxorubicin , cyclophosphamide , ifosfamide , etoposide . Time elapse previous therapy must ≥ 3 week systemic therapy , ≥ 2 week radiation therapy major surgery . Patients undergone autologous hematopoietic stem cell transplantation eligible recovered toxicity therapy Patients receive allogeneic hematopoietic stem cell transplantation eligible 6 month procedure provide evidence active graftversushost disease immunosuppressive treatment discontinue least 30 day . Patients central nervous system disease eligible enrollment receive prior radiotherapy surgery sit central nervous system metastatic disease , glucocorticoid least 4 week , overt evidence neurological deficit ≥ 6 week completion brain irradiation . Patients legal representative ( patient &lt; 18 year old ) must able read , understand provide write informed consent participate trial . Females childbearing potential well male partner must agree use effective form contraception study 6 month follow last dose study medication . Clinically significant unrelated illness would , judgment treat physician , compromise patient 's ability tolerate investigational agent likely interfere study procedure result . Patients baseline QTc &gt; 480 msec . Inability swallow capsule . Known hypersensitivity component niraparib prior hypersensitivity reaction class drug . Known hypersensitivity reaction temozolomide component , dacarbazine ( DTIC ) enrol ARM 1 irinotecan component enrol ARM 2 Concomitant use investigational anticancer agent ( ) . Pregnant patient patient breast feed . Subjects capable pregnancy ( post menarche postmenopausal , define 12 month since final menstrual period ) must negative pregnancy test within 7 day prior first dose . Other clinically significant malignant disease diagnose within previous 5 year , exclude intraepithelial cervical neoplasia nonmelanoma skin cancer . Active central nervous system disease . Known history MDS . Known persistent ( &gt; 4 week ) ≥ Grade 2 neutropenia , ≥ Grade 2 thrombocytopenia &gt; Grade 3 anemia prior cancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>